Bisphosphonate-related Osteonecrosis of the Jaw (MRONJ)
On this page
Direct answer
Exposed necrotic jaw bone persisting beyond eight weeks in a patient taking an antiresorptive or antiangiogenic agent — without radiotherapy — defines medication-related osteonecrosis of the jaw (MRONJ), the bisphosphonate-related form the original and commonest. The potent nitrogen-containing bisphosphonates (zoledronic acid, pamidronate) given intravenously for bone metastases and myeloma carry the highest risk, reported in roughly 1-10 per cent of exposed patients, while oral bisphosphonates for osteoporosis (alendronate) sit below 0.1 per cent; denosumab, an anti-RANKL monoclonal antibody, produces a clinically similar lesion with risk comparable to intravenous bisphosphonates, which is why the umbrella term MRONJ replaced BRONJ. The jaws dominate because their high remodelling turnover is precisely what these drugs freeze: osteoclast suppression plus impaired angiogenesis and local infection (almost always after an extraction or ill-fitting denture) leaves avascular bone that cannot exfoliate. Management is staged — chlorhexidine and antibiotics for symptomatic control, mucosal coverage and sequestrectomy for advanced disease — and the entire game is prevention by dental clearance before therapy starts.
What you must remember
- Definition (AAOMS): exposed bone, or bone probed through a fistula, persisting more than 8 weeks in a patient on antiresorptive or antiangiogenic therapy, with no history of radiation.
- Drug ranking: intravenous zoledronic acid and pamidronate (oncology) highest, commonly quoted around 1-10 per cent; denosumab similar order (roughly 1-2 per cent, reversible on stopping); oral alendronate lowest (about 0.01-0.1 per cent, rising after 4-5 years); antiangiogenics add risk, especially combined with bisphosphonates.
- Site and trigger: mandible over maxilla (about 2:1); over 90 per cent follow dentoalveolar surgery — extraction the dominant precipitant, denture trauma next.
- Pathogenesis trio: osteoclast poisoning (impaired remodelling), antiangiogenic effect, and bacterial biofilm colonising exposed cortex, Actinomyces frequently identified.
- AAOMS staging: stage 0 — non-specific findings (pain, sclerotic bone) without exposed bone; stage 1 — exposed bone without infection; stage 2 — exposed bone with infection (pain, erythema, purulence); stage 3 — exposed bone plus extension beyond the alveolar bone (pathologic fracture, extraoral fistula, sinus-floor or inferior canal involvement).
- Prevention protocol: dental assessment with extractions and periodontal care completed before starting the drug, ideally with a 2-3 week healing window (a "drug holiday" before invasive treatment remains debated); appliance relief; impeccable hygiene during therapy.
- Management by stage: stage 0-1 — chlorhexidine rinses, review; stage 2 — add systemic antibiotics (penicillins, metronidazole) and pain control; stage 3 — surgical debridement or resection with mucosal closure; hyperbaric oxygen and teriparatide as adjuncts in refractory cases.
- Oncology versus osteoporosis calculus: in oncology the drug is life-prolonging and the risk accepted; in osteoporosis, elective jaw surgery may justify a managed pause.
A worked preventive pathway
A 62-year-old woman with breast cancer and bone metastases is scheduled for monthly zoledronic acid. The dental sequence NEET-MDS frames as a scenario runs: panoramic radiograph and examination now; extract hopeless teeth and debride periodontitis before the first infusion, allowing 2-3 weeks of mucosal healing; adjust prostheses over thin flanges; document a maintenance plan; and if an extraction becomes unavoidable later, use atraumatic technique, primary closure, chlorhexidine and antibiotic prophylaxis. When she presents six months on with a non-healing socket exposing yellowish bone without pus, staging gives MRONJ stage 1: chlorhexidine, serial review, no elective mucosal trauma. When pain and purulence appear (stage 2): culture-guided antibiotics and antiseptic irrigation; if a sequestrum separates, limited sequestrectomy with tension-free closure converts a chronic wound to a healing one. Every upstream step (pre-therapy clearance) is worth more than any downstream surgery.
Where students slip
The definitional trap is timing and cause: candidates accept exposed bone as osteonecrosis without excluding prior radiotherapy (that is osteoradionecrosis) and without the eight-week criterion. The second slip is calling every exposed socket bone in a bisphosphonate patient MRONJ immediately; early post-extraction bone can exfoliate normally, so the eight-week clock matters. Third, candidates overstate osteoporosis risk: oral alendronate risk is roughly two orders of magnitude below intravenous zoledronate, and quoting "ten per cent" for a woman on weekly alendronate is a fail-grade error. Finally, the BRONJ-to-MRONJ renaming (2014, AAOMS) exists because denosumab replicates the phenotype — itself a one-mark favourite.
Frequently asked questions
What are the diagnostic criteria for MRONJ?
Exposed or fistula-communicating necrotic jaw bone persisting over 8 weeks, current or prior antiresorptive or antiangiogenic therapy, and no history of radiation to the region.
Which drug carries the highest risk of osteonecrosis of the jaw?
Intravenous zoledronic acid (with pamidronate), used in oncology — reported risk roughly 1-10 per cent, far above oral bisphosphonates used for osteoporosis.
How does denosumab-related ONJ differ from bisphosphonate-related ONJ?
Clinically and histologically nearly identical, but denosumab's effect on remodelling is reversible within months of stopping, whereas bisphosphonates persist in bone for years.
What is stage 2 MRONJ?
Exposed necrotic bone with evidence of infection — pain, erythema, purulence — managed with systemic antibiotics, chlorhexidine and antiseptic irrigation, with or without local debridement.
Which preventive dental measures precede antiresorptive therapy?
Screening radiographs, extraction of hopeless teeth, periodontal therapy and prosthetic adjustment before the first dose, with a healing window before treatment begins.